SCHEMBL3869324

SCHEMBL3869324

O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccc(CCl)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 15/20 0.78
PDGFRA P16234 13/20 0.78
BCR P11274 12/20 0.78
PDGFRB P09619 9/20 0.78
SRC P12931 7/20 0.78
PRKCA P17252 4/20 0.78
PRKCD Q05655 3/20 0.78
PRKD3 O94806 1/20 0.78
PRKCG P05129 1/20 0.78
PRKCB P05771 1/20 0.78
PRKCH P24723 1/20 0.78
PRKCI P41743 1/20 0.78
PRKCE Q02156 1/20 0.78
PRKCQ Q04759 1/20 0.78
PRKCZ Q05513 1/20 0.78
PRKD1 Q15139 1/20 0.78
KIT P10721 4/20 0.77
ABL2 P42684 2/20 0.77
SYK P43405 1/20 0.73
MAPK8 P45983 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903223 0.91 ABL1 (0.70) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL3863391 0.91 PDGFRA (0.78) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL10208 0.89 ABL1 (0.82) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL1430 0.88 ABL1 (1.00) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL9197 0.88 ABL1 (1.00) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL3860520 0.87 PDGFRA (0.87) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL723757 0.87 PDGFRA (1.00) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL9565 0.87 ABL1 (1.00) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL9763 0.87 ABL1 (1.00) ABL1PDGFRABCRPDGFRBSRC
SCHEMBL20204862 0.87 ABL1 (1.00) ABL1PDGFRABCRPDGFRBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) 2006-09-28 US claimed
EP-1395261-B1 PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES GPC BIOTECH AG (DE) 2006-06-28 EP claimed
US-20030176443-A1 Pyridylpyrimidine derivatives as effective compounds against prion diseases GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) 2003-09-18 US claimed
US-7595323-B2 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof IL YANG PHARM. CO., LTD. (KR) 2009-09-29 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
EP-1721609-A2 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases GPC Biotech AG (DE) 2006-11-15 EP disclosed
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) 2006-09-28 US disclosed
EP-1395261-B1 PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES GPC BIOTECH AG (DE) 2006-06-28 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed
US-20040248918-A1 Anticancer agents IL YANG PHARM. CO., LTD. 2004-12-09 US disclosed
WO-2004099186-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF IL YANG PHARM CO., LTD. (KR) 2004-11-18 WO disclosed
US-20030176443-A1 Pyridylpyrimidine derivatives as effective compounds against prion diseases GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176443-A1 Pyridylpyrimidine derivatives as effective compounds against prion diseases PRNP, PPM1D, PPM1F ABL1 901/4885PDGFRA 2586/4885BCR 1338/4885
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases PRNP, PPM1D, PPM1F ABL1 904/4885PDGFRA 2913/4885BCR 1230/4885
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885PDGFRA 373/4885BCR 2315/4885
US-20040248918-A1 Anticancer agents BRDT, CHIA, RNASE1 ABL1 1106/4885PDGFRA 239/4885BCR 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.